Weight Loss
Tirzepatide
Next-gen weight loss
This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.
About Tirzepatide
Dual GIP and GLP-1 receptor agonist offering enhanced weight management benefits.
How it works
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both incretin pathways instead of just one. This dual action produces superior weight loss results vs semaglutide alone. Phase 3 trials showed up to 22.5% body weight loss.
Clinical evidence
The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) randomized 2,539 adults with obesity to tirzepatide 5/10/15 mg vs placebo. At 72 weeks, mean weight reductions were 15.0%, 19.5%, and 20.9% on the active arms vs 3.1% on placebo — the highest weight-loss outcomes recorded for a pharmacological intervention at the time. SURMOUNT-2 confirmed efficacy in patients with type 2 diabetes, and the SURPASS program (Frias et al., 2021) demonstrated superior HbA1c reduction vs semaglutide head-to-head. Tirzepatide's dual GIP+GLP-1 mechanism appears to drive both stronger appetite suppression and improved metabolic flexibility.
Benefits
Tirzepatide vs. Mounjaro / Zepbound
Same active ingredient. Compounded at an FDA-registered 503A pharmacy.
Dosing
Your prescribing physician determines the right dose, schedule, and how it's administered — based on your goals, medical history, and lab work. Your personalized protocol is provided after your consultation.
Important safety information
+
Possible side effects
Do not use if you have
If you experience severe side effects, call 911 or go to your nearest emergency room.
Frequently asked about Tirzepatide
Same active ingredient. Mounjaro (diabetes) and Zepbound (weight loss) are the Eli Lilly brand names. Our compounded tirzepatide is the same molecule from an FDA-registered 503A pharmacy at a fraction of the cost.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine (2022) · PMID 35658024
- Garvey WT, Frias JP, Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) · Lancet (2023) · PMID 37385275
- Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) · New England Journal of Medicine (2021) · PMID 34170647
- Inagaki N, Takeuchi M, Oura T, et al.. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono) · The Lancet Diabetes & Endocrinology (2022) · PMID 35468322
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Read more about Tirzepatide
Get started today
Ready to start with Tirzepatide?
Free assessment. Licensed physicians. Money-back guarantee if not approved.